Abercrombie & Fitch, through its subsidiaries, is a retailer which primarily sells its products through its wholly-owned store and direct-to-consumer channels, as well as through various third-party wholesale, franchise and licensing arrangements. The company provides an assortment of apparel, personal care products and accessories for men, women and children under the Hollister, Abercrombie & Fitch and abercrombie kids brands. The company has operations in North America, Europe, Asia and the Middle East. The company's operating segments are brand-based: Hollister and Abercrombie, the latter of which includes the company's Abercrombie & Fitch and abercrombie kids brands.
Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The company is engaged in the commercial sales of Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Also, the company markets branded Ampyra (dalfampridine), an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP) approved to improve walking in adults with multiple sclerosis.
Activision Blizzard is a developer and publisher of interactive entertainment content and services. The company's segments include: Activision Publishing, Inc., which is a developer and publisher of interactive software products and entertainment content, particularly in console platform; Blizzard Entertainment, Inc. which is a developer and publisher of interactive software products and entertainment content, particularly for the personal computer platform; and King Digital Entertainment, which is a developer and publisher of interactive entertainment content and services, particularly on mobile platforms, such as Google Inc.'s Android and Apple Inc.'s iOS.
Advanced Micro Devices is a semiconductor company. The company primarily provides: x86 microprocessors, as standalone devices or as incorporated into an accelerated processing unit (APU), chipsets; discrete and integrated graphics processing units (GPUs), and professional GPUs; and server and embedded processors and semi-custom System-on-Chip (SoC) products and technology for game consoles. The company also licenses portions of its intellectual property portfolio. The company has two segments: Computing and Graphics, which consists of desktop and notebook processors, and chipsets; and Enterprise, Embedded and Semi-Custom, which consists of discrete and professional GPUs.
Aimmune Therapeutics is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The company's Characterized Oral Desensitization ImmunoTherapy (CODIT?), is designed to desensitize patients to food allergens. The company's primary CODIT product candidate, AR101 is an investigational biologic for the treatment of patients with peanut allergy. The company is also exploring a product candidate designed to treat multi-nut allergy, including walnut allergy. The company is also conducting research and development activities for CODIT targeting other food allergies, including cow's milk allergy.
Albireo Pharma is a biopharmaceutical company focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company's primary product candidate, A4250, is used for the treatment of progressive familial intrahepatic cholestasis (PFIC), pruritus associated with PFIC, Alagille syndrome and biliary atresia. The company's product candidates in addition to A4250 include elobixibat, which is approved in Japan for the treatment of chronic constipation, and A3384, which is a product candidate to treat bile acid malabsorption.
Alexion Pharmaceuticals is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the development and commercialization of therapies. The company is engaged in complement inhibition and has developed and commercialized two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria, as well as the complement inhibitor to treat atypical hemolytic uremic syndrome and anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. In addition, the company has two enzyme replacement therapies for patients with metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency.
Allena Pharmaceuticals is a late-stage, clinical biopharmaceutical company focused on developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company's main product candidate, reloxaliase, is an oral enzyme therapeutic that it is developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease (CKD) and other serious kidney disease. The company's second product candidate, ALLN-346, is being developed for patients with hyperuricemia and moderate to severe CKD.
Alphabet is a holding company. The company has two segments: Google and Other Bets. Google includes the company's main products such as Ads, Android, Chrome, Google Cloud, Google Maps, Google Play, Hardware (including Nest), Search, and YouTube. The company provides a range of products across screens and formats. Also, the company delivers both performance advertising and brand advertising. Other Bets includes businesses such as Access, Calico, CapitalG, GV, Verily, Waymo, and X. Other Bets primarily engages in the sale of internet and TV services through Access as well as licensing and research and development services through Verily.
Alpine Select AG. Alpine Select AG (Alpine) is a Switzerland-based investment company. The Company's emphasis lies on securities, quoted or otherwise, of Swiss and foreign corporations, which are subject to particular corporate events such as spin-offs, acquisitions, recapitalizations and reorganizations, or circumstances including valuation anomalies or technical market situations. Alpine Select AG's investment portfolio is primarily comprised of quoted securities. As of December 31, 2011, the Company's investments included Absolute Invest AG, Absolute Private Equity AG, AIRE GmbH & Co KGaA, Atrium V Ltd, BB Biotech AG and HBM Bioventures AG, among others. The Company operates through its wholly owned subsidiary, Sumara AG.
Amazon.com serves consumers through its online and physical stores. The company also manufactures and sells electronic devices, including Kindle e-readers, Fire tablets, Fire TVs, and Echo devices, and the company develops and produces media content. The company provides programs that enable sellers to grow their businesses, sell their products in its stores, and fulfill orders through the company The company serves developers and enterprises of various sizes, including start-ups, government agencies, and academic institutions, through its Amazon Web Services segment, which provides a set of global compute, storage, database, and other service offerings. In addition, the company provides services, such as advertising.
American Eagle Outfitters is a multi-brand retailer. The company operates retail stores and online at www.ae.com and www.aerie.com. The company provides a range of apparel and accessories for men and women under the American Eagle Outfitters brand, and intimates, apparel and personal care products for women under the Aerie brand. The company operates stores in the U.S., Canada, Mexico, Hong Kong, and China. The company also has license agreements with third-parties to operate American Eagle Outfitters and Aerie stores throughout Asia, Europe, India, Latin America and the Middle East. The company also operates two other brands, Tailgate, a vintage, sports-inspired apparel brand, and Todd Snyder New York, a menswear brand.
AnaptysBio is a clinical stage biotechnology company developing antibody product candidates. Etokimab, the company's anti-IL-33 antibody drug candidate, inhibits the activity of the interleukin-33 cytokine that is applicable to the treatment of atopic inflammatory disorders, such as moderate-to-severe atopic dermatitis, eosinophilic asthma, chronic rhinosinusitis with nasal polyps, and potentially other allergic conditions. ANB019 inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases including generalized pustular psoriasis and palmoplantar pustulosis. The company's wholly-owned pipeline includes anti-inflammatory checkpoint receptor modulator antibodies.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating disease through the inhibition of the complement system, which is a component of the immune system, at the level of C3, the central protein in the complement cascade. The company's clinical program targets C3 with Phase 3 clinical trials of its main product candidate, APL-2, in multiple indications. APL-2 has the potential to be a treatment that address the limitations of existing treatment options or provide a treatment option. The company is also conducting a Phase 2 trial of APL-2 in glomerular diseases, including C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy and lupus nephritis.
Apple designs, manufactures and markets mobile communication and media devices and personal computers, and sells a variety of related software, services, accessories, and third-party digital content and applications. The company's products and services include iPhone?, iPad?, Mac?, Apple Watch?, AirPods?, Apple TV?, HomePod?, a portfolio of consumer and personnel software applications, iOS, macOS?, watchOS? and tvOS? operating systems, iCloud?, Apple Pay? and a variety of other accessory, service and support offerings. The company sells and delivers digital content and applications through the iTunes Store?, App Store?, Mac App Store, TV App Store, Book Store and Apple Music?.
Applied Genetic Technologies is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The company focuses on the field of ophthalmology, where it has clinical programs in X-linked retinitis pigmentosa and achromatopsia. The company also has preclinical programs in optogenetics and adrenoleukodystrophy, which is a disease of the central nervous system (CNS), and several other ophthalmology, CNS and otology indications. The company has developed technological capabilities in the design, construction and manufacture of viral vectors using adeno-associated virus technology.
Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The company's product candidates comprised of: NYX 2925, which is a small molecule N-methyl-D-aspartate receptors (NMDAr) modulator being developed for the treatment of chronic pain; NYX-783, which is a small-molecule NMDAr modulator in development for the treatment of post-traumatic stress disorder; NYX-458, which is a small-molecule NMDAr modulator in development for the treatment of Parkinson's disease cognitive impairment; and AGN-241751, which is for the treatment of depressive disorder.
Aravive is clinical-stage biotechnology company focused on developing therapies that target survival pathways for both advanced solid tumors as well as hematologic malignancies. The company's primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression. The U.S. Food and Drug Administration, designated as a Fast Track development program the investigation of the company's primary development candidate, Aravive-S6-500, for platinum-resistant recurrent ovarian cancer.
Arbutus Biopharma is a therapeutic solutions company focused on discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection. Co.'s HBV pipeline consists of multiple drug candidates, with differing and complementary mechanisms of action. The candidates include: RNAi 1.0 (ARB-1467), which is Co.'s main RNA Interference (RNAi) HBV candidate designed to eliminate HBV surface antigen expression in patients chronically infected with HBV; RNAi 2.0 (ARB-1740), Co.'s follow-on RNAi HBV candidate; and Core Protein/ Capsid Assembly Inhibitors (AB-423), which is being developed as oral therapeutics for the treatment of chronic HBV infection.
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer immunotherapies. The company has four clinical-stage product candidates: AB928, which is an orally bioavailable, reversible antagonist of the adenosine 2a and adenosine 2b receptors; AB680, which is a reversible and selective inhibitor of the CD73 enzyme; AB122, which is a human antibody with similar binding affinity and other characteristics to the marketed anti-PD-1 antibodies pembrolizumab and nivolumab; and AB154, which is a humanized antibody that inhibits an immune checkpoint target involved in a pathway that plays both inhibitory and stimulatory roles in the immune system.
Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
Arvinas is a biopharmaceutical company. Through its subsidiaries, the company is engaged in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases.
AVROBIO is a clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The company's gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. The company's pipeline is comprised of four lentiviral-based gene therapy programs, including AVR-RD-01 for the treatment of Fabry disease, AVR-RD-02 for the treatment of Gaucher disease, AVR-RD-04 for the treatment of cystinosis and AVR-RD-03 for the treatment of Pompe disease.
Bed, Bath & Beyond is an omnichannel retailer providing products, services and solutions for the home and life events. The company operates an ecommerce platform consisting of various websites and applications, including bedbathandbeyond.com, bedbathandbeyond.ca, harmondiscount.com, and facevalues.com. The company sells an assortment of domestics merchandise and home furnishings. Domestics merchandise includes categories such as bed linens and related items, bath items and kitchen textiles. Home furnishings include categories such as kitchen and tabletop items, fine tabletop, basic housewares, general home furnishings (including furniture and wall decor), consumables and certain juvenile products.
Best Buy provides computing and mobile phones, consumer electronics, appliances, entertainment, services and other products. The company operates two reportable segments: Domestic, which is comprised of the operations in all states, districts and territories of the U.S. under various brand names including Best Buy, bestbuy.com, Best Buy Direct, Best Buy Express, Best Buy Mobile, Geek Squad, GreatCall, Magnolia and Pacific Kitchen and Home; and International, which is comprised of all operations in Canada and Mexico under the brand names Best Buy, Best Buy Express, Best Buy Mobile, Geek Squad and the domain names bestbuy.ca and bestbuy.com.mx.
Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for people living with neurological and neurodegenerative diseases, including in areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis. The company's marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis.
BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company's commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
bluebird bio is a clinical-stage biotechnology company focused on developing potentially transformative gene therapies for severe genetic diseases and cancer. The company's clinical programs in severe genetic diseases include its LentiGlobin? product candidate as a treatment for transfusion-dependent ?-thalassemia and sickle cell disease and its Lenti-D? product candidate as a treatment for cerebral adrenoleukodystrophy. bb2121 and bb21217, the company's clinical-stage product candidates in oncology, are CAR T cell product candidates for the treatment of multiple myeloma.
Blueprint Medicines is a therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy. The company's drug candidates are: avapritinib, which targets KIT and PDGFRa mutations; BLU-667, which targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or fusions; BLU-554, which targets FGFR4, a kinase that is aberrantly activated in a defined subset of patients with hepatocellular carcinoma, the common type of liver cancer; and BLU-782, which is for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the activin-like kinase 2 gene, ACVR1.
CarMax is a holding company. Through its subsidiaries, the company is engaged as a retailer of used vehicles. The company operates in two segments: CarMax Sales Operations, which sells used vehicles, purchases used vehicles from customers and other sources, sells related products and services, and arranges financing options for customers; and CarMax Auto Finance, which consists of finance operation that provides vehicle financing to customer buying retail vehicles from the company The company's products and services include retail merchandising, wholesale auctions, extended protection plans, reconditioning and service, and customer credit.
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker drug discovery platform. The company's product candidates include edasalonexent for the treatment of Duchenne muscular dystrophy as well as additional rare disease, CAT-5571 for the treatment of cystic fibrosis, and CAT-4001 for the treatment of Friedreich's ataxia and amyotrophic lateral sclerosis. The company holds rights to all of its product candidates throughout the world.
Cidara Therapeutics is a biotechnology company focused on the discovery, development and commercialization of anti-infectives for the treatment of diseases. The company is developing a pipeline of product and development candidates, with an initial focus on fungal infections. The company's primary product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of invasive fungal infections. In addition, the company's proprietary Cloudbreak? platform is designed to discover compounds that directly kill pathogens and also direct a patient's immune system to attack and eliminate pathogens.
Clearside Biomedical is a clinical biopharmaceutical company developing pharmacological therapies to restore and preserve vision for people with serious eye diseases. The company's suprachoroidal injection platform is a patented approach for delivering pharmacotherapy to the back of the eye in the anatomic structure known as the suprachoroidal space. The company's main product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide formulated for administration via suprachoroidal injection, for the treatment of macular edema associated with uveitis. The company is also developing XIPERE for the treatment of diabetic macular edema.
CytomX Therapeutics is clinical-stage, oncology-focused biopharmaceutical company with a class of investigational antibody therapeutics based on its Probody? technology platform the treatment of cancer. The company uses its platform to create proprietary cancer immunotherapies against clinically-validated targets. The company's two programs, CX-072, a wholly owned PD-L1-targeting Probody therapeutic and CX-2009, wholly owned CD166-targeting Probody drug conjugate. Both CX-072 and CX-2009 are part of PROCLAIM (Probody Clinical Assessment in Man), an international umbrella clinical trial program that provides clinical trial sites with access to the company's novel therapies under one central protocol.
Deckers Outdoor is engaged in designing, marketing and distributing footwear, apparel and accessories. The company markets its products primarily under five brands. The UGG brand is comprised of a line of footwear, apparel and accessories for women, men and children. The HOKA brand is a line of footwear and apparel. The Teva brand's product line includes sandals, shoes, and boots. Sanuk brand is comprised of casual shoe and sandal categories. Other brands consist of Koolaburra by UGG brand, a casual footwear fashion using sheepskin and other plush materials. The company's retail stores are primarily UGG brand concept and UGG brand outlet stores.
Denali Therapeutics is a biopharmaceutical company that engaged in discovering and developing therapeutics to defeat neurodegenerative diseases. The company's core programs are its leucine-rich repeat kinase 2 (LRRK2) inhibitor program to address Parkinson's disease and its receptor interacting serine/threonine protein kinase 1 (RIPK1) inhibitor program for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company's product candidates in LRRK2 program, DNL201 and DNL151, are potent, selective and brain-penetrant small molecule for Parkinson's disease. The company's product candidate in RIPK1 inhibitor program, DNL747, a selective and brain-penetrant small molecule for ALS and Alzheimer's disease.
Eiger BioPharmaceuticals is a clinical stage biopharmaceutical company focused on bringing to market product candidates for the treatment of rare diseases. The company's product candidate pipeline includes four programs: Lonafarnib (LNF) in Hepatitis Delta Virus (HDV), which is an orally bioavailable, farnesylation inhibitor in Phase 3 clinical trials for HDV infection; Peginterferon Lambda in HDV, which is a late-stage, type III interferon that stimulates immune responses; LNF in Progeria and Progeroid Laminopathies (PL), which the company develops LNF for treatment of PL; and Avexitide in Post-Bariatric Hypoglycemia (PBH), which is a peptide that the company is developing as a treatment for PBH.
Electronic Arts develops, markets, publishes and distributes games, content and services that can be played and watched on a variety of platforms, including game consoles, personal computers, and mobile phones. The company markets and sells its games and services through digital distribution channels and through retail channels. Digitally, the company's console games and services can be purchased through third-party storefronts. In its games and services, the company utilizes brands that it either wholly own or license from others. The company develops and publishes games and services across genres. Within and alongside its games, the company provides live services, including in-game purchases, downloadable content, and esports.
Entasis Therapeutics is a holding company. Through its subsidiary, the company is clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria.
Epizyme is a late-stage biopharmaceutical company that is focused on the treatment for people with cancer and other diseases through the discovery, development, and commercialization of epigenetic medicines. The company's lead product candidate, tazemetostat, is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase for the treatment of a range of cancer types in multiple treatment settings, and its G9a program, EZM8266, is used for the treatment of sickle cell disease. The company owns the global development and commercialization rights to tazemetostat outside of Japan. Eisai Co. Ltd holds the rights to develop and commercialize tazemetostat in Japan.
Fate Therapeutics is a clinical-stage biopharmaceutical company. The company's immuno-oncology product candidates include: FATE-NK100, which is a natural killer (NK) cell cancer immunotherapy comprised of adaptive memory NK cells; and FT500, which is an off-the-shelf NK cell cancer immunotherapy for the treatment of solid tumors; and FT516, which is an off-the-shelf immunotherapy for the treatment of cancer. The company's immuno-regulation product candidates include: ProTmune?, which is an investigational programmed cellular immunotherapy for use as an allogeneic hematopoietic cell transplantation cell graft; and FT301, which is an off-the-shelf, immuno-regulatory cell product candidate.
Five Prime Therapeutics is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The company's key product candidates are: FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 that it is studying in a clinical trial in multiple cancers; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that the company is studying in a clinical trial in multiple cancers; and Cabiralizumab (FPA008) is an antibody that the company and its partner Bristol-Myers Squibb Company, or BMS, are studying in clinical trials in multiple cancers in combination with BMS's PD-1 immune checkpoint inhibitor, Opdivo? (nivolumab).
G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company's product pipeline includes three clinical candidates: trilaciclib, a short-acting intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that preserves hematopoietic stem and progenitor cells and immune system function; lerociclib, an oral CDK4/6 inhibitor that inhibits tumor proliferation and growth; and G1T48, an oral selective estrogen receptor degrader that inhibits estrogen receptor driven tumor proliferation.
The Gap is an apparel retail company. The company provides apparel, accessories, and personal care products for men, women, and children under the Old Navy, Gap, Banana Republic, Athleta, Intermix, and Hill City brands. The company has stores in the U.S., Canada, the U.K., France, Ireland, Japan, Italy, China, Hong Kong, Taiwan, and Mexico, and has franchise agreements with unaffiliated franchisees to operate Old Navy, Gap, and Banana Republic stores throughout Asia, Europe, Latin America, the Middle East, and Africa. Under these agreements, third parties operate stores that sell apparel and related products under the company's brand names.
Global Blood Therapeutics is a clinical-stage biopharmaceutical company determined to discover, develop and deliver treatments that provide hope to underserved patient communities. The company's primary product candidate is voxelotor, an oral, once-daily therapy that modulates hemoglobin's affinity for oxygen, which inhibits hemoglobin polymerization in sickle cell disease (SCD). The company is evaluating voxelotor in adult and adolescent patients with SCD in a Phase 3 clinical trial. The company is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in adolescent and pediatric patients with SCD in a Phase 2a clinical trial.
Idera Pharmaceuticals is a biopharmaceutical company. The company's focus is on its Toll-like receptor, or TLR, agonist, tilsotolimod (IMO-2125), for oncology. The company's TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The company is developing tilsotolimod, via intratumoral injection, for the treatment of anti-PD1 refractory metastatic melanoma in combination with ipilimumab, an anti-CTLA4 antibody marketed as Yervoy? by Bristol-Myers Squibb Company (BMS). The company is also evaluating intratumoral tilsotolimod in combination with nivolumab, an anti-PD1 antibody marketed as Opdivo? by BMS, and ipilimumab for the treatment of multiple solid tumors in a Phase 2 trial.
Intellia Therapeutics is a genome editing company focused on developing therapeutics utilizing a biological tool known as Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9). This is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. The company utilizes its CRISPR/Cas9 platform across two areas: in vivo applications, in which CRISPR/Cas9 is therapy, delivered to target cells within the body; and ex vivo applications, in which CRISPR/Cas9 creates therapy of engineered human cells.
Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. The company's marketed product, Ocaliva? (obeticholic acid or OCA), is an farnesoid X receptor agonist approved in the U.S., the European Union and several other jurisdictions for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition to, the company is developing OCA for multiple indications, including nonalcoholic steatohepatitis.
IVERIC bio is a biopharmaceutical company focusing on the development of therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company's therapeutics portfolio consists of Zimura? (avacincaptad pegol), which is a C5 complement inhibitor, and its program of High temperature requirement A serine peptidase 1 protein, or HtrA1, inhibitors.Co. has clinical trials ongoing evaluating Zimura for the treatment of geographic atrophy, which is a late-stage form of dry age-related macular degeneration; and autosomal recessive Stargardt disease, which is an orphan inherited retinal disease that also may result in loss of vision.
Kala Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics using the company's proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company's MPPs are selectively-sized nanoparticles and have proprietary coatings enhancing the mobility of drug particles through mucus and preventing drug particles from becoming trapped and eliminated by mucus. The company's product candidates include treatments for post-operative inflammation and pain following ocular surgery, temporary relief of the signs and symptoms of dry eye disease and retinal diseases.
Karyopharm Therapeutics is a clinical-stage pharmaceutical company. The company is focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has discovered and is developing small molecule Selective Inhibitors of Nuclear Export (SINE), compounds that inhibit the nuclear export protein (XPO1). The company's SINE compounds were the first oral XPO1 inhibitors in clinical development. The company's focus is on seeking the commercialization of its primary drug candidate, selinexor (KPT-330), as an oral agent in cancer indications with clinical need, initially for hematologic malignancies.
Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. The company's key product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of farnesyl transferase. The company's second product candidate is KO-947, a selective small molecule inhibitor of extracellular signal related kinase, which the company is developing as a potential treatment for patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway. The company's product candidate is KO-539, a selective small molecule inhibitor of the menin-mixed lineage leukemia, or menin-MLL, protein-protein interaction.
L Brands is a holding company. Through its subsidiaries, the company is a specialty retailer of women's intimate and other apparel, personal care, beauty and home fragrance products. The company sells its merchandise through company-owned specialty retail stores in the U.S., Canada, the U.K., Ireland and Greater China, and through its websites and other channels. The company's other international operations are primarily through franchise, license and wholesale partners. The company has three reportable segments: Victoria's Secret, Bath & Body Works and Victoria's Secret and Bath & Body Works International. The company operates the following retail brands: Victoria's Secret, PINK and Bath & Body Works.
Lexicon Pharmaceuticals is a biopharmaceutical company. The company discovers the functions and pharmaceutical utility of genes and uses those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. The company is commercializing XERMELO? (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. The company is also developing sotagliflozin as a treatment for type 1 and type 2 diabetes; LX9211 as a treatment for neuropathic pain; and LX2761 as a treatment for diabetes.
Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using the company's PRINT? technology to transform the lives of patients. The company is focused on the development of its product candidates for which it holds commercial rights: LIQ861, which is being evaluated for the treatment of pulmonary arterial hypertension, a disease caused by the hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death; and LIQ865, which is an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure.
MacroGenics discovers and develops antibody-based therapeutics to modulate the human immune response for the treatment of cancer. The company has a pipeline of product candidates in human clinical testing, including immuno-oncology programs, that have been created using its proprietary antibody-based technology platforms. The company is developing product candidates that target various tumor-associated antigens, including HER2. The company is also developing a franchise of molecules that target programmed cell death protein 1 (PD-1). The company is developing two bispecific DART product candidates that engage PD-1 and lymphocyte-activation gene 3, as well as PD-1 and cytotoxic T-lymphocyte-associated protein 4.
Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to extend the curative capability of stem cell transplant, gene therapy, genome editing and cell therapy to more patients. The first conditioning program in the company's portfolio is C100, under which it is developing antibody-drug conjugates (ADC) that specifically deplete host HSCs and immune cells. The company's key conditioning program, C200, is designed to specifically deplete HSCs and disease-causing cells. The company's lead ADC product candidate targets CD117, also known as c-Kit, which is highly expressed on HSCs and leukemia cells, making it an ideal target for conditioning across sets of diseases.
Marvell Technology Group is a semiconductor provider of application-specific products. The company is focused on the development of System-on-a-Chip devices, utilizing its technology portfolio of intellectual property in the areas of analog, mixed-signal, digital signal processing, and embedded and standalone integrated circuits. The company develops integrated hardware platforms along with software that incorporates digital computing technologies. In storage, the company is engaged in fibre channel products and data storage controller solutions spanning cloud, enterprise, edge and personal computing markets. The company's networking products include ethernet solutions, embedded processors and WiFi connectivity solutions.
MasterCard is a technology company, in the payments industry that connects consumers, financial institutions, merchants, governments, digital partners, businesses and other organizations worldwide, enabling them to use electronic forms of payment instead of cash and checks. The company creates a range of payment solutions and services using its brands, including Mastercard?, Maestro? and Cirrus?. The company facilitates the switching (authorization, clearing and settlement) of payment transactions and delivers related products and services. The company also provides offerings such as safety and security products, information services and consulting, loyalty and reward programs and issuer and acquirer processing.
Mersana Therapeutics is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) for cancer patients. The company's primary product candidate, XMT-1536, is an ADC targeting NaPi2b, an antigen broadly expressed in ovarian cancer and non small cell lung cancer. In addition, the company has established research and development partnerships with Merck KGaA and Asana Biosciences for the development and commercialization of additional ADC product candidates against a limited number of targets selected by the company's partners based on its Dolaflexin platform.
Micron Technology provides memory and storage solutions. The company's portfolio of memory and storage technologies include DRAM, NAND, NOR Flash, and 3D XPoint memory. The company has four business units: Compute and Networking Business, which includes memory products sold into cloud server, enterprise, client, graphics, and networking markets; Mobile Business, which includes memory products sold into smartphone and other mobile-device markets; Storage Business, which includes Solid-State Drives and component-level solutions sold into enterprise and cloud, client, and consumer storage markets; and Embedded Business, which includes storage products sold into automotive, industrial, and consumer markets.
Microsoft is a technology company. The company develops and supports software, services, devices, and solutions. The company provides an array of services, including cloud-based solutions as well as solution support and consulting services. The company also delivers relevant online advertising. The company's products include operating systems; cross-device productivity applications; server applications; business solution applications; desktop and server management tools; software development tools; and video games. The company also designs, manufactures, and sells devices, including personal computers, tablets, gaming and entertainment consoles, other devices, and related accessories.
Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing treatments for orphan endocrine diseases. The company's product candidates include: livoletide (AZP-531), which is a treatment for Prader-Willi syndrome, a genetic endocrine disease characterized by hyperphagia; and nevanimibe (ATR-101), which focuses on treating patients with classic congenital adrenal hyperplasia, a monogenic adrenal disease that requires lifelong treatment with exogenous cortisol. The company is also investigating nevanimibe in a clinical trial for the treatment of patients with endogenous Cushing's syndrome, an endocrine disease characterized by excessive cortisol production from the adrenal glands.
Miragen Therapeutics is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapeutics with a specific focus on microRNAs and their role in certain diseases. The company has three product candidates, cobomarsen, remlarsen and MRG-110, in clinical development. Cobomarsen is an inhibitor of miR-155, which is a microRNA that is found at abnormally high levels in malignant cells of several blood cancers. Remlarsen is a replacement for miR-29, a microRNA that is found at abnormally low levels in a number of pathological fibrotic conditions. MRG-110 is an inhibitor of miR-92, a microRNA expressed in endothelial cells.
MyoKardia is a clinical stage biopharmaceutical company engaged in a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company's initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The company's main product candidate, mavacamten, is initially being developed for the treatment of hypertrophic cardiomyopathy. The company's second candidate, MYK-491, is being studied in a Phase 2a multiple-ascending dose clinical trial in patients with stable heart failure.
Nintendo is mainly engaged in the development, manufacture, and sale of home-use game hardware/software and peripheral equipment as well as software under the name of "Nintendo DS," "Nintendo 3DS," "Game Boy," "Nintendo 64,"" Game Boy Advance," "Wii," "Nintendo GameCube," "Game Boy Color" and "e-Reader (trading card games)." Co.'s principal software trademarks include "Pokemon," "Super Mario Bros.," "The Legend of Zelda," "STARFOX64" and others. Co. also provides online games and repair services. In addition, Co. is involved in the manufacture and sale of Japanese playing cards called "Karuta," playing cards and board games, as well as the management of intellectual property rights.
Nordstrom is a fashion retailer providing a selection of brand-name and private label apparel, shoes, cosmetics and accessories for women, men, young adults and children. The company serves customers through two businesses: Full-Price and Off-Price. The company's operations consist of the company's Nordstrom U.S. and Canada full-line stores, U.S. and Canada Nordstrom Rack stores, Jeffrey boutiques, Last Chance clearance stores, Trunk Club clubhouses and Nordstrom Local. Additionally, customers are served online through Nordstrom.com, Nordstromrack.com, HauteLook and TrunkClub.com.
NVIDIA engages in graphics processing unit (GPU)-based visual computing and accelerated computing platforms. The company has two reportable segments, GPU and Tegra Processor, which are based on a single underlying architecture. The company's GPU product brands include GeForce for gamers; Quadro for designers; Tesla and DGX for artificial intelligence data scientists and big data researchers; and GRID for cloud-based visual computing users. The company's Tegra brand integrates an entire computer onto a single chip, and incorporates GPUs and multi-core CPUs to drive supercomputing for autonomous robots, drones, and cars, as well as for game consoles and mobile gaming and entertainment devices.
Pacira BioSciences is a holding company. Through its subsidiaries, the company is a pharmaceutical company focused on delivering non-opioid pain management and regenerative health solutions to surgeons and anesthesiologist. The company's marketed product, EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, the company's extended release drug delivery technology, that delivers bupivacaine over time for extended analgesia.
Paratek Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics. The company has created small molecules derived from the minocycline core structure. The company's NUZYRA? (omadacycline) is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections, caused by susceptible pathogens. In addition, SEYSARA? (sarecycline) is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, with respect to which the company has licensed in the United States certain rights to Almirall, LLC.
Purple Innovation designs and manufactures a range of comfort technology products, including mattresses, pillows, cushions and other products, using its proprietary Hyper-Elastic Polymer? technology. The company markets and sells its products through direct-to-consumer online channels, wholesale partners and third-party online retailers.
Replimune Group is a clinical-stage biotechnology company focused on the development of oncolytic immunotherapies to treat cancer. The company's primary product candidate, RP1, is a selectively replicating version of herpes simplex virus 1 that expresses GALV-GP R(-) and human GM-CSF. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4, a protein that inhibits the immune response to tumors. The company has designed its RP3 product candidate to express immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-).
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of aging-related diseases. The company's initial focus is on the development of RTB101, an orally administered, small molecule, target of rapamycin complex 1 inhibitor, alone and in combination with other mechanistic target of rapamycin inhibitors such as everolimus, as an immunotherapy program designed to improve immune function and thereby reduce the incidence of respiratory tract infections in the elderly regardless of the causative pathogen.
Sage Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines to treat life-altering central nervous system disorders. The company's principal product candidate is ZULRESSO? (brexanolone) injection, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's other product candidate is SAGE-217, an oral compound that is being developed for PPD and major depressive disorder. The company also has a portfolio of other compounds that target GABAA receptors, which include SAGE-324 and SAGE-689. The company's second area of focus is the development of compounds that target the NMDA receptor, which include SAGE-718.
Sangamo BioSciences is a clinical stage biotechnology company focused on translating science into genomic medicines using its platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company is focused on these therapeutic areas: inherited metabolic diseases, central nervous system diseases and inflammatory and autoimmune diseases. The company has an ongoing clinical trial evaluating SB-318 for the treatment of Mucopolysaccharidosis Type I. The company is also evaluating SB-FIX in a clinical trial which is designed to assess the SB-FIX in adults with severe hemophilia B. The company is evaluating ST-400 in a clinical trial to evaluate the adult subjects with beta-thalassemia.
Scholar Rock is a biopharmaceutical company. The company's primary product candidate, SRK-015, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. The company's second product candidate is SRK-181 and is being developed for the treatment of cancers resistant to checkpoint blockade therapies, such as anti-PD1 antibodies. The company's third antibody program targets the signaling of bone morphogenetic protein 6, another member of the TGF? superfamily, which is involved in a set of biological processes in various parts of the body.
Sutro Biopharma is a clinical stage drug discovery, development and manufacturing company. The company focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
Synlogic is a biopharmaceutical company focused on improving its drug discovery and development platform for Synthetic Biotic? medicines, which are designed using synthetic biology to genetically reprogram beneficial microbes to treat metabolic and inflammatory diseases and cancer. The company's therapeutics programs include: SYNB1020, which is an oral therapy for the treatment of hyperammonemia, including patients with liver disease such as hepatic encephalopathy and patients with urea cycle disorders; and SYNB1618, which is an oral therapy for the treatment of phenylketonuria, a metabolic disease in which the amino acid phenylalanine accumulates in the body as a result of genetic defects.
Syros Pharmaceuticals is a biopharmaceutical company engaged in the non-coding regulatory region of the genome to develop a new wave of medicines that control the expression of genes. The company's primary product candidates are: SY-1425, a selective retinoic acid receptor alpha agonist that is used to treat acute myeloid leukemia patients; SY-1365, a selective inhibitor of cyclin-dependent kinase 7 (CDK7), that is being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors; and SY-5609, a CDK7 inhibitor that can be administered orally, which is being evaluated in investigational new drug application, enabling preclinical studies.
Taiwan Semiconductor Manufacturing is a foundry in the semiconductor industry which engages mainly in the manufacturing, selling, packaging, testing and computer-aided design of integrated circuits and other semiconductor devices and the manufacturing of masks. Co. also engages in the researching, developing, designing, manufacturing and selling of solid state lighting devices and related applications products and systems, and renewable energy and efficiency related technologies and products. Co.'s products include logic semiconductors, mixed-signal/radio frequency semiconductors, CMOS image sensor semiconductors and high voltage semiconductors.
Take-Two Interactive Software is a developer, publisher and marketer of interactive entertainment for consumers. The company develops and publishes products principally through its two wholly-owned labels Rockstar Games and 2K, as well as its Private Division label and Social Point, a developer of mobile games. The company's products are designed for console gaming systems such as the Sony Computer Entertainment, Inc. PlayStation?4, Microsoft Corporation Xbox One?, and Xbox 360?, the Nintendo Switch, and personal computers, including smartphones and tablets. The company delivers its products through physical retail, digital download, online platforms and cloud streaming services.
Ubisoft Entertainment is an international independent developer, publisher & distributor of video games. Co. centers its business activities on developing, publishing & distributing video games for portable & home consoles, the PC, smartphones & tablets in both physical & online formats: high-definition with games for Xbox 360, PlayStation®3 & PC; casual with games for Nintendo®, KINECT & PlayStation®3 Move; and online for on-line games. Co.'s catalogue includes various types of games: Action/Adventure, Shooters, Sports, Strategy, Simulation, TV and Movie licenses, Games for everyone and Driving. Co.'s trademarks include Assassin's Creed®, Rainbow Six® Vegas 2, and Rayman Raving Rabids®.
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The company's product categories are: biologics, which include Crysvita? (burosumab) for the treatment of X-linked hypophosphatemia and Mepsevii? (vestronidase alfa) for the treatment of Mucopolysaccharidosis VII; small molecules, which includes UX007 for the treatment of long-chain fatty acid oxidation disorders; and gene therapy, which includes DTX301 for the treatment of patients with ornithine transcarbamylase deficiency and DTX401 for the treatment of patients with glycogen storage disease type Ia.
United Therapeutics is a biotechnology company. The company markets and sells four commercial therapies to treat pulmonary arterial hypertension (PAH): Remodulin? (treprostinil) Injection; Tyvaso? (treprostinil) Inhalation Solution; Orenitram? (treprostinil) Extended-Release Tablets; and Adcirca? (tadalafil) Tablets. The company also markets and sells an oncology product, Unituxin? (dinutuximab) Injection for treatment of high-risk neuroblastoma. The company also engages in research and development of new indications and formulations and delivery devices for its existing products, as well as new products to treat PAH and other conditions. The company also engages in organ transplantation-related technologies.
Unum Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is intended to be used in combination with a wide range of tumor-specific antibodies to target different tumor types. The company's product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development.
Urban Jakarta Propertindo Tbk PT Formerly known as Urban Jakarta Propertindo PT. PT Urban Jakarta Propertindo Tbk is an Indonesia based company primarily engaged in property development and management.
Visa is a payments technology company. The company's primary products consist of business solutions, which include small business, corporate cards, purchasing cards, virtual accounts, and disbursement accounts; credit, which allows consumers and businesses to access credit to pay for goods and services; debit, which allows consumers and small businesses to purchase goods and services using funds in their demand deposit accounts; prepaid, which addresses consumer-use cases and needs including, general purpose reloadable and payroll; and global ATM, which provides account holders with cash access through issuing and acquiring partnerships with financial institutions and independent ATM operators.
oyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. The company is focused on neurological diseases with adeno-associated virus, gene therapy approach that either increases or decreases the production of a specific protein. The company's pipeline includes: Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis; Huntington's disease; Friedreich's ataxia; tau-related diseases including Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy; Alpha-synuclein related diseases for Parkinson's disease and other synucleinopathies; and severe, chronic pain.
Wayfair is a holding company. Through its e-commerce business model, the company provides customers with browsing, merchandising and product discovery for products from various suppliers. The company has online selections of furniture, decor, decorative accents, housewares, seasonal decor and other home goods. The company's mobile app also provides customers a way to shop for their home from their home using its View in Room 3D augmented reality tool. The company's sites include: Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold. Wayfair is the only one of the company's sites that also operates internationally, operating as Wayfair.ca in Canada, Wayfair.co.uk in the U.K. and Wayfair.de in Germany.
Western Digital is a developer, manufacturer, and provider of data storage devices and solutions. The company's portfolio of technology and products address the following markets: Client Devices, which consist of hard disk drives (HDDs) and solid state drives (SSDs) for computing devices, flash-based embedded storage products, and flash-based memory wafers and components; Data Center Devices and Solutions, which consist of enterprise HDDs and enterprise SSDs, data center software and system solutions; and Client Solutions, which consist of HDDs and SSDs embedded into external storage products and removable flash-based products, such as cards, universal serial bus flash drives and wireless drives.
Williams-Sonoma is a retailer of products for the home. The company has two reportable segments, e-commerce and retail. The e-commerce segment has the following merchandise strategies: Williams Sonoma, Pottery Barn, Pottery Barn Kids, West Elm, PBteen, Williams Sonoma Home, Rejuvenation and Mark and Graham, which sell the company's products through its e-commerce websites and direct-mail catalogs. The retail segment, which includes the company's franchise operations, has the following merchandise strategies: Williams Sonoma, Pottery Barn, Pottery Barn Kids, West Elm and Rejuvenation, which sell the company's products through its retail stores.
Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat diseases with unmet medical needs. The company is developing a suite of clinical-stage drug candidates from its proprietary XmAb? technology platforms that are designed to treat cancer, autoimmune and allergic diseases, and other conditions. The company's protein engineering efforts and the XmAb technologies are focused on the portion of the antibody that interacts with multiple segments of the immune system and controls antibody structure. This portion, referred to as the Fc domain, is constant and interchangeable among antibodies.
XOMA is a biotech company engaged in discovering and developing therapeutic candidates. The company has a pipeline of monoclonal antibodies and technologies: X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, which targets interleukin 2 and has been recognized as a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline that includes several functional antibody antagonists targeting PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism.
Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. The company is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Since our founding in 1955, Wedbush has been a leader in the financial industry providing our clients with a wide range of services; including institutional sales, correspondent clearing services, equity research, corporate and municipal finance, equity market making, fixed income trading, prime brokerage, and wealth management. Headquartered in Los Angeles, with 100 registered offices, the firm focuses on dedicated service, client financial safety, continuity, and advanced technology.
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.